Literature DB >> 2945892

Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells.

R J North.   

Abstract

The results of this study confirm results published by others by showing that sublethal whole-body irradiation of mice bearing immunogenic tumors can result in complete tumor regression. The results show, in addition, that irradiation-induced tumor regression can be prevented by infusion, after irradiation, of Ly-1+,2-,L3T4+ suppressor T cells from the spleens of donors bearing an established tumor, but not by infusion of normal spleen cells. This evidence, plus the demonstration that irradiation fails to cause regression of tumors growing in immunocompetent mice, is consistent with the hypothesis that irradiation-induced regression is immunologically mediated, and that it depends on the ability of irradiation to preferentially eliminate suppressor T cells. By using passive transfer assays to measure the production of effector T cells and suppressor T cells against time of tumor growth, it was shown that irradiation of tumor-bearing mice on day 5 of tumor growth resulted in a failure to generate suppressor T cells on the one hand, and in a sustained production, effector T cells on the other. In other words, irradiation prevented the concomitant antitumor immune response from being downregulated by suppressor T cells. However, giving radiation on day 1 of tumor growth, in contrast to giving it 3-6 d later, caused immunodepression and enhancement of tumor growth. This is in keeping with published evidence showing that, whereas resting effector T cells are highly radiosensitive, antigen-activated effector T cells are relatively radioresistant. It is suggested that the radioresistance of activated effector T cells, coupled with the radiosensitivity of activated suppressor T cells, is the reason for the selectivity of ionizing radiation for suppressor T cells and why a tumor needs to be palpable to undergo regression in response to radiation therapy.

Entities:  

Mesh:

Year:  1986        PMID: 2945892      PMCID: PMC2188446          DOI: 10.1084/jem.164.5.1652

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

Review 1.  Ionizing radiation and the immune response.

Authors:  R E Anderson; N L Warner
Journal:  Adv Immunol       Date:  1976       Impact factor: 3.543

2.  Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

Authors:  R J North; E S Dye
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

Review 3.  Down-regulation of the antitumor immune response.

Authors:  R J North
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

Review 4.  The murine antitumor immune response and its therapeutic manipulation.

Authors:  R J North
Journal:  Adv Immunol       Date:  1984       Impact factor: 3.543

5.  Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression.

Authors:  E S Dye; R J North
Journal:  Transplantation       Date:  1984-06       Impact factor: 4.939

6.  Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Activation of mouse lymphocytes inhibits induction of rapid cell death by x-irradiation.

Authors:  J W Lowenthal; A W Harris
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

8.  Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population.

Authors:  K E Hellström; I Hellström; J A Kant; J D Tamerius
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

  8 in total
  34 in total

1.  APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair.

Authors:  Roni Nowarski; Ofer I Wilner; Ori Cheshin; Or D Shahar; Edan Kenig; Leah Baraz; Elena Britan-Rosich; Arnon Nagler; Reuben S Harris; Michal Goldberg; Itamar Willner; Moshe Kotler
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

2.  Radiation enhances regulatory T cell representation.

Authors:  Evelyn L Kachikwu; Keisuke S Iwamoto; Yu-Pei Liao; John J DeMarco; Nzhde Agazaryan; James S Economou; William H McBride; Dörthe Schaue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-17       Impact factor: 7.038

3.  Effect of advanced ageing on the ability of mice to cause tumour regression in response to immunotherapy.

Authors:  P L Dunn; R J North
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

4.  T-cell responses to survivin in cancer patients undergoing radiation therapy.

Authors:  Dörthe Schaue; Begonya Comin-Anduix; Antoni Ribas; Li Zhang; Lee Goodglick; James W Sayre; Annelies Debucquoy; Karin Haustermans; William H McBride
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

5.  Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

Authors:  Hilko Ardon; Stefaan Van Gool; Isabel Spencer Lopes; Wim Maes; Raf Sciot; Guido Wilms; Philippe Demaerel; Patricia Bijttebier; Laurence Claes; Jan Goffin; Frank Van Calenbergh; Steven De Vleeschouwer
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

6.  The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.

Authors:  Michael Spiotto; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Sci Immunol       Date:  2016-09-30

Review 7.  Radiotherapy and immunotherapy: a beneficial liaison?

Authors:  Ralph R Weichselbaum; Hua Liang; Liufu Deng; Yang-Xin Fu
Journal:  Nat Rev Clin Oncol       Date:  2017-01-17       Impact factor: 66.675

Review 8.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

Authors:  Paul Andrew Antony; Nicholas P Restifo
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

9.  Administration of cyclophosphamide changes the immune profile of tumor-bearing mice.

Authors:  Pu Liu; Jade Jaffar; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

Review 10.  Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.

Authors:  Robert E Roses; Jashodeep Datta; Brian J Czerniecki
Journal:  Radiat Res       Date:  2014-07-03       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.